Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome

Journal of Clinical Endocrinology and Metabolism

Volumn 82, Issue 7, 1997, Pages 2108-2116

  Ehrmann, David A ^a,c   Schneider, David J ^b   Sobel, Burton E ^b   Cavaghan, Melissa K ^a   Imperial, Jacqueline ^a   Rosenfield, Robert L ^a   Polonsky, Kenneth S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; TROGLITAZONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL EXAMINATION; FEMALE; FIBRINOLYSIS; GLUCOSE INTOLERANCE; HUMAN; HYPERANDROGENISM; INSULIN RELEASE; INSULIN SENSITIVITY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; STEROIDOGENESIS;

ADULT; ANDROGENS; CHROMANS; FEMALE; FIBRINOLYSIS; GLUCOSE; GLUCOSE TOLERANCE TEST; GONADOTROPINS; HUMANS; INSULIN; INSULIN RESISTANCE; LEUPROLIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYCYSTIC OVARY SYNDROME; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0030855145     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.82.7.2108     Document Type: Article

References (75)

1. Dunaif A. 1992 Insulin resistance and ovarian hyperandrogenism. Endocrinologist. 2:248-260.
2. Dunaif A, Segal K, Futterweit W, Dobrjansky A. 1989 Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 38:1165-1174.
3. Dunaif A, Segal K, Shelley D, Green G, Dobrjansky A, Licholai T. 1992 Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes. 41:1257-1266.
4. O'Meara N, Blackman J, Ehrmann DA, et al. 1993 Defects in beta cell function and insulin action in functional ovarian hyperandrogenism. J Clin Endocrinol Metab. 76:1241-1247.
5. Ehrmann D, Cavaghan M, Imperial J, Sturis I, Rosenfield R, Polonsky K. 1997 Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 82:524-530.
6. Ehrmann D, Barnes R, Rosenfield R. 1995 Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism. Endocr Rev. 16:322-353.
7. Ehrmann D, Sturis J, Byrne M, Karrison T, Rosenfield R, Polonsky K. 1995 Insulin secretory defects in polycystic ovary syndrome: relationship to insulin sensitivity and family history of non-insulin dependent diabetes mellitus. J Clin Invest. 96:520-527.
8. Dunaif A, Finegood D. 1996 β-Cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab. 81:942-947.
9. Ehrmann D, Rosenfield R, Barnes R, Karrison T. 1996 A longitudinal study of glucose tolerance in women with polycystic ovary syndrome [Abstract]. Proc of the Int Congr of Endocrinol. 1996. (Abstract) OR26-28.
10. Dunaif A, Graf M, Mandeli J, Laumas V, Dobrjansky A. 1987 Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance and/or hyperinsulinemia. J Clin Endocrinol Metab. 65:499-507.
11. Barbieri R, Makris A, Randall R, Daniels C, Kistner R, Ryan K. 1986 Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J Clin Endocrinol Metab. 62:904-910.
12. Cara J, Rosenfield R. 1988 Insulin-like growth factor-I and insulin potentiate luteinizing hormone-induced androgen sythesis by rat ovarian theca-interstitial cells. Endocrinology. 123:733-739.
13. Stuart D, Nagamani M. 1992 Acute augmentation of plasma androstenedione and dehydroepiandrosterone by euglycemic insulin infusion: evidence for a direct effect of insulin on ovarian steroidogenesis. In: Dunaif A, Givens J, Haseltine F, Merriam G, eds. Current issues in endocrinology and metabolism: polycystic ovary syndrome. Cambridge: Blackwell; 279-288.
14. Dahlgren E, Janson P, Johansson S, Lapidus L, Oden A. 1992 Polycystic ovary sydrome and risk for myocardial infarction. Acta Obset Gynecol Scand. 71:599-604.
15. Dahlgren E, Lapidus L, Janson P, Lindstedt G, Johansson S, Tengborn L. 1994 Hemostatic and metabolic variables in women with polycystic ovary syndrome. Fertil Steril. 61:455-460.
16. Guzick D, Talbott E, Sutton-Tyrrell K, Herzog H, Kuller L, Wolfson SJ. 1996 Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case-control study. Am J Obstet Gynecol. 174:1224-1232.
17. Talbott E, Guzick D, Clerici A, et al. 1995 Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol. 15:821-826.
18. Birdsall M, Farquhar C, White H. 1997 Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. Ann Intern Med. 126:32-35.
19. Schneider D, Sobel B. 1991 Augmentation of synthesis of plasminogen activator inhibitor type-1 by insulin and insulin-like growth factor type-1: implications for vascular disease in hyperinsulinemic states. Proc Natl Acad Sci USA. 88:9959-9963.
20. Schneider D, Sobel B. 1996 Synergistic augmentation of expression of PAI-1 induced by insulin, VLDL, and fatty acids. Coronary Artery Dis. 7:813-817.
21. Shimomura I, Funahashi T, Takahashi M, et al. 1996 Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med. 2:800-803.
22. Nordt T, Sawa H, Fujii S, Sobel B. 1995 Induction of plasminogen activator inhibitory type-1 (PAI-1) by proinsulin and insulin in vivo. Circulation. 91:764-770.
23. Cavaghan M, Ehrmann D, Byrne M, Polonsky K. Treatment with the oral antidiabetic agent troglitazone improves β-cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest. In press.
24. Nolan J, Ludvik B, Beerdsen P, Joyce M, Olefsky J. 1994 Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med. 331:1188-1193.
25. Dunaif A, Scott D, Finegood D, Quintana B, Whitcomb R. 1996 The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab. 81:3299-3306.
26. Ehrmann D, Rosenfield R, Barnes R, Brigell D, Sheikh Z. 1992 Detection of functional ovarian hyperandrogenism in women with androgen excess. N Engl J Med. 327:157-162.
27. Adams J, Polson D, Franks S. 1986 Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J. 293:355-359.
28. WHO Expert Committee. 1980 Second report on diabetes mellitus. Technical Rep Ser 646. Geneva: WHO.
29. Valdes C, Elkind-Hirsch K. 1991 Intravenous glucose tolerance test-derived insulin sensitivity changes during the menstrual cycle. J Clin Endocrinol Metab. 72:642-646.
30. Diamond M, Somonson D, DeFronzo R. 1989 Menstrual cyclicity has a profound effect on glucose homeostasis. Fertil Steril. 52:204-208.
31. Kissebah A. 1992 Upper body obesity: abnormalities in the metabolic profile and the androgenic/estrogenic balance. In: Dunaif A, Givens J, Haseltine F, Merriam G, eds. Current issues in endocrinology and metabolism: polycystic ovary syndrome. Cambridge: Blackwell; 359-374.
32. Mazess R, Barden H, Bisek J, Hanson J. 1990 Dual-energy x-ray absorptiometry for total body and regional bone-mineral and soft-tissue composition. Am J Clin Nutr. 51:1106-1112.
33. Bergman R, Phillips L, Cobelli C. 1981 Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and β-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest. 68:1456-1467.
34. O'Meara N, Sturis J, Van Cauter E, Polonsky K. 1993 Lack of control by glucose of ultradian insulin secretory oscillations in impaired glucose tolerance and in non-insulin-dependent diabetes mellitus. J Clin Invest. 92:262-271.
35. Sturis J, Van Cauter E, Blackman J, Polonsky K. 1991 Entrainment of pulsatile insulin secretion by oscillatory glucose infusion. J Clin Invest. 87:439-445.
36. Morgan C, Lazarow A. 1963 Immunoassay of insulin: two antibody systems: plasma insulin levels of normal, subdiabetic and diabetic rats. Diabetes. 12:115-126.
37. Faber O, Binder C, Markussen J, et al. 1978 Characterization of seven C-peptide antisera. Diabetes. 27:170-177.
38. Moll G, Rosenfield R, Helke J. 1981 Estradiol-testosterone binding interactions and free plasma estradiol under physiological conditions. J Clin Endocrinol Metab. 52:868-876.
39. Barnes R, Rosenfield R, Burstein S, Ehrmann D. 1989 Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome. N Engl J Med. 320:559-565.
40. Angles-Cano E. A spectrophotometric solid-phase fibrin-tissue plasminogen activator activity assay (SOFIA-t-PA) for high-fibrin-affinity tissue plasminogen activators. Anal Biochem. 153:201-210.
41. Chmielewska J, Wiman B. 1986 Determination of plasminogen activator and its "fast" inhibitor in plasma. Clin Chem. 32:482-485.
42. Bergman R. 1989 Lilly Lecture 1989. Toward physiological understanding of glucose tolerance: minimal model approach. Diabetes. 38:1512-1527.
43. Kahn S, Prigeon R, McCulloch D, et al. 1993 Quantification of the relationship between insulin sensitivity and B-cell function in human subjects Evidence for a hyperbolic function. Diabetes. 42:1663-1672.
44. Van Cauter E, Mestrez F, Sturis J, Polonsky K. 1992 Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes. 41:368-377.
45. Eaton R, Allen R, Schade D, Erickson K, Standefer J. 1980 Prehepatic insulin production in man: kinetic analysis using peripheral connecting peptide behavior. J Clin Endocrinol Metab. 51:520-528.
46. Polonsky K, Licinio-Paixao J, Given B, et al. 1986 Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients. J Clin Invest. 77:98-105.
47. Sturis J, Polonsky K, Shapiro E, Blackman J, O'Meara N, Van Cauter E. 1992 Abnormalities in the ultradian oscillations of insulin secretion and glucose levels in type 2 (non-insulin-dependent) diabetic patients. Diabetalogia. 35:681-689.
48. Jenkins G, Watts D. 1968 Spectral analysis and its applications. San Francisco: Holden Day.
49. Pasquali R, Casimirri F, Venturoli D, et al. 1994 Body fat distribution has weight-independent effects on clinical, hormonal, and metabolic features of women with polycystic ovary syndrome. Metabolism. 6:706-713.
50. Saltiel A, Olefsky J. 1996 Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 45:1661-1669.
51. Lehmann J, Moore L, Smith-Oliver T, Wilkinson W, Willson T, Kliewer S. 1995 An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor (PPAR). J Biol Chem. 270:12953-12956.
52. Keller H, Wahli W. 1993 Peroxisome proliferator-activated receptors: a link between endocrinology and nutrition? Trends Endocrinol Metab 4:291-296.
53. Ibrahimi A, Teboul L, Gaillard D, et al. 1994 Evidence for a common mechanism of action for free fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells. Mol Pharmacol. 46:1070-1076.
54. Brandes R, Arad R, Bar-Tana J. 1995 Inducers of adipose conversion activate transcription promoted by a peroxisome proliferators response element in 3T3-L1 cells. Biochem Pharmacol. 50:1949-1951.
55. Kliewer S, Lenhard J, Willson T, Patel I, Morris D, Lehmann J. 1995 A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor and promotes adipocyte differentiation. Cell. 83:813-819.
56. Rosetti L, Giaccari A, DeFronzo R. 1990 Glucose toxicity. Diabetes Care 13:610-629.
57. Leahey J, Bonner-Weir S, Weir GC. 1992 β-Cell dysfunction induced by chronic hyperglycemia: current ideas on mechanism of impaired glucose-induced insulin secretion. Diabetes Care. 15:442-453.
58. Yki-Jarvinen H. 1992 Glucose toxicity. Endocr Rev. 13:415-431.
59. Masuda K, Okamoto Y, Tsuura Y, et al. 1995 Effects of troglitazone (CS-045) on insulin secretion in isolated rat pancreatic islets and HIT cells: an insulinotropic mechanism distinct from glibenclamide. Diabetologia. 38:24-30.
60. Berkowitz K, Peters R, Kjos S, et al. 1996 Effect of troglitazone on insulin sensitivity and pancreatic B-cell function in women at high risk for NIDDM. Diabetes. 45:1572-1579.
61. Rosenfield R, Barnes R, Cara J, Lucky A. 1990 Dysregulation of cytochrome P450c17α as the cause of polycystic ovary syndrome. Fertil Steril. 53:785-791.
62. Franks S, White D. 1993 Prevalence of and etiological factors in polycystic ovarian syndrome. Ann NY Acad Sci. 687:112-114.
63. Sahin Y, Kelestimur F. 1993 17-Hydroxyprogesterone response to buserelin testing in the polycystic ovary syndrome. Clin Endocrinol (Oxf). 39:151-155.
64. Ibañez L, Potau N, Virdis R, et al. 1993 Postpubertal outcome in girls diagnosed of premature pubarche during childhood: increased frequency of functional ovarian hyperandrogenism. J Clin Endocrinol Metab. 76:1599-1603.
65. White D, Leigh A, Wilson C, Donaldson A, Franks S. 1995 Gonadotrophin and gonadal steroid response to a single dose of a long-acting agonist of gonadotrophin-releasing hormone in ovulatory and anovulatory women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 42:475-481.
66. Rosenfield R, Barnes R, Ehrmann D. 1994 Studies of the nature of 17-hydroxyprogesterone hyperresponsiveness to gonadotropin releasing hormone agonist challenge in functional ovarian hyperandrogenism. J Clin Endocrinol Metab. 79:1686-1692.
67. Barbieri R. 1992 Human ovarian 17-ketosteroid oxidoreductase: unique characteristics of the granulosa-luteal cell and stromal enzyme. Am J Obstet Gynecol. 166:1117-1123.
68. Nestler J, Jakubowicz D. 1996 Decreases in ovarian cytochrome P450c17α activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med. 335:617-623.
69. McGill J, Schneider D, Arfken C, Lucore C, Sobel B. 1994 Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes. 43:104-109.
70. Folsom A, Qamhieh H, Wing R, et al. 1993 Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults. Arterioscler. Thromb. 13:162-169.
71. Swislocki A, Hoffman B, Reaven G. 1989 Insulin resistance, glucose intolerance and hyperinsulinemia in patients with hypertension. Am J Hypertension. 2:419-423.
72. Sampson M, Kong C, Patel A, Unwin R, Jacobs H. 1996 Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. Clin Endocrinol (Oxf). 45:623-629.
73. Andersen P, Seljeflot I, Abdelnoor M, et al. 1995 Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome. Metabolism. 44:611-616.
74. Velazquez EM, Mendoza SG, Wang P, Glueck CJ. 1997 Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein (a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. Metabolism. 46:454-457.
75. Alessi M, Juhan-Vague I, Kooistra T, DeClerck P, Collen D. 1988 Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line HepG2. Thromb Haemost. 60:491-494.